Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
651,165

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Haemonetics Plasma Arm Advances, Blood Center Sluggish

On Jul 13, we issued an updated research report on Haemonetics Corporation (HAE).

    Why Is It the Perfect Time to Buy Thermo Fisher (TMO) Stock?

    Thermo Fisher Scientific, Inc. (TMO) is on a healthy growth trajectory of late and has rallied 17.7% over the past three months.

      BioTelemetry (BEAT) Acquires LifeWatch for $280 Million

      BioTelemetry Inc. (BEAT) enhances its position in the wireless medicine space, enlarges product profile and customer base in cardiac monitoring and diagnostic services with LifeWatch buyout.

        Hill-Rom (HRC) at 52-Week High: What's Driving the Stock?

        Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $84.17 on Jul 14.

          Avantor to Acquire VWR, Consolidation Promises Global Gains

          On Jul 14, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).

            DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando

            DaVita Inc. (DVA) recently acquired Dr. Rahn Shaw's practices, Park Avenue Medical, Inc. and Winter Park Health Center, Inc., each located in Orlando.

              Abiomed (ABMD) Scores a Strong Buy Right Now: Here's How

              With solid growth prospects Abiomed (ABMD) carries a Zacks Rank #1 (Strong Buy) which is an attractive pick at present.

                Medtronic Enrolls First Patient Under STOP AF First Trial

                Medtronic (MDT) recently announced the first enrollment to its STOP AF First clinical trial.

                  Zimmer Biomet's Preliminary Q2 Numbers Solid, CEO Steps Down

                  Indiana-based Zimmer Biomet Holdings, Inc. (ZBH), a leading player in the global musculoskeletal space, recently announced second-quarter 2017 preliminary results.

                    Edwards Emerges Strong on FDA Nods, International Prospect

                    On Jul 11, we issued an updated research report on the leading molecular diagnostic company, Edwards Lifesciences Corporation (EW).

                      Here's Why You Should Add ResMed to Your Portfolio Now

                      California-based ResMed, Inc. (RMD) has been on a healthy growth trajectory of late.

                        CVS Health's MinuteClinic Joins EOHN for Workplace Healthcare

                        MinuteClinic, the retail medical clinic of CVS Health Corporation (CVS), announced a tie-up with the Alere eScreen Occupational Health Network.

                          Express Scripts Rides High on Increased Generic Utilization

                          On Jul 10, we issued an updated research report on St. Louis, MO-based pharmacy benefit manager Express Scripts Holding Company (ESRX).

                            PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation

                            PAREXEL International Corporation (PRXL) was recently nominated as a CEO Cancer Gold Standard employer by CEO Roundtable on Cancer.

                              RTI Surgical at a 52-Week High: What's Driving the Stock?

                              Share price of RTI Surgical, Inc. (RTIX), based in Alachua, FL, scaled a new 52-week high of $6.00 on Jul 10, eventually closing a bit lower at $5.65.

                                Neogen Introduces Test for Listeria in Environmental Samples

                                Neogen Corporation (NEOG) recently developed Listeria Right Now test system.

                                  Myriad Genetics to Grow with Study Successes, New Alliances

                                  On Jul 6, we issued an updated research report on Myriad Genetics, Inc. (MYGN).

                                    Investors Look for Gains as Abbott Labs Set to Acquire Alere

                                    On majority of Alere shareholders' recent approval in favor of the merger with Abbott (ABT), the deal is now expected to close by the end of third-quarter 2017.

                                      ResMed Sees Potential in SDB Market, Eyes Global Growth

                                      On Jul 6, we issued an updated research report on San Diego, CA-based ResMed, Inc. (RMD).

                                        Baxter and TAU Ink New Licensing Agreements through Ramot

                                        Baxter International (BAX) has recently teamed up with Tel Aviv University, Israel's largest research and teaching university (TAU), on two new licensing agreements through Ramot.

                                          Edwards Lifesciences' INSPIRIS RESILIA Valve Wins FDA Nod

                                          Edwards Lifesciences Corporation (EW) recently announced the receipt of FDA approval for its INSPIRIS RESILIA aortic valve.

                                            Will Walgreens Gain from Revised Rite Aid Agreement?

                                            The new agreement would enable Walgreens Boots Alliance (WBA) to buy nearly half of the Rite Aid business at a deal value, almost one-third of the original price.

                                              Omnicell (OMCL) Rides on Acquisitions Amid Tough Competition

                                              On Jul 4, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).

                                                Abbott Freestyle Libre System Gets Health Canada License

                                                Abbott Laboratories (ABT) recently announced the receipt of Health Canada license for its FreeStyle Libre Flash Glucose Monitoring System.

                                                  Here's Why You Can Buy Quest Diagnostics Stock Right Now

                                                  Quest Diagnostics Incorporated (DGX) is on a healthy growth trajectory of late.